Bulaquine

Bulaquine (CDRI 80/53) is a potent antimalarial agent which is an analogue of Primaquine (HY-12651A) . Bulaquine affects multiple metabolism pathways and shows inhibition effect on Plasmodium cynomolgi infection. Bulaquine can be used for the research of malaria[1][2][3].

Product Specifications

CAS Number

[79781-00-3]

Product Name Alternative

CDRI 80/53; Elubaquine

UNSPSC

12352005

Target

Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bulaquine.html

Solubility

10 mM in DMSO

Smiles

C/C(NCCCC(NC1=CC(OC)=CC2=C1N=CC=C2)C)=C3C(OCC/3)=O

Molecular Formula

C21H27N3O3

Molecular Weight

369.46

References & Citations

[1]Noel S, et al. Identification of differentially expressed genes after acute exposure to bulaquine (CDRI 80/53) in mice liver. Basic Clin Pharmacol Toxicol. 2008 Dec;103 (6) :522-9.|[2]Dutta GP, et al. Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys. Am J Trop Med Hyg. 1989 Dec;41 (6) :635-7.|[3]Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26 (3) :145-51.Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26 (3) :145-51.